Glucagon-like peptide-1 agonist transdermal - TransPharma

Drug Profile

Glucagon-like peptide-1 agonist transdermal - TransPharma

Alternative Names: ViaDerm-GLP1 agonist; ViaDor-GLP1 agonist

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator TransPharma Medical
  • Class Glucagon-like peptides
  • Mechanism of Action Glucagon like peptide 1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Type 2 diabetes mellitus

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Type-2-diabetes-mellitus in Israel (Transdermal, Patch)
  • 23 Feb 2011 Pharmacokinetics data from a phase Ib trial in Type-2 diabetes mellitus released by TransPharma
  • 23 Feb 2011 TransPharma completes a phase Ib trial in Type-2 diabetes mellitus in Israel
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top